254 related articles for article (PubMed ID: 20129455)
1. [The renin-angiotensin system in hypertension and in cardiovascular and renal diseases: highlights of the World Congress of Nephrology 2009]].
Romet M
Nephrol Ther; 2010 Jan; 6 Spec No 1():H10-3. PubMed ID: 20129455
[No Abstract] [Full Text] [Related]
2. [Debate concerning the optimal blockage of the renin-angiotensin system].
Choukroun G
Nephrol Ther; 2010 Jan; 6 Spec No 1():H1-9. PubMed ID: 20129454
[No Abstract] [Full Text] [Related]
3. [Overview of the RAAS in renal damage and hypertension].
Yamamoto T; Nishiyama A
Nihon Jinzo Gakkai Shi; 2010; 52(2):87-91. PubMed ID: 20415226
[No Abstract] [Full Text] [Related]
4. [The prorenin receptor].
Bracquart D; Cousin C; Contrepas A; Nguyen G
J Soc Biol; 2009; 203(4):303-10. PubMed ID: 20122388
[TBL] [Abstract][Full Text] [Related]
5. Have the renin-angiotensin-aldosterone system perturbations in cardiovascular disease been exhausted?
Mansur SJ; Hage FG; Oparil S
Curr Cardiol Rep; 2010 Nov; 12(6):450-63. PubMed ID: 20827517
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular and renal pathologic implications of prorenin, renin, and the (pro)renin receptor: promising young players from the old renin-angiotensin-aldosterone system.
Balakumar P; Jagadeesh G
J Cardiovasc Pharmacol; 2010 Nov; 56(5):570-9. PubMed ID: 21108514
[TBL] [Abstract][Full Text] [Related]
7. Recent changes in the landscape of combination RAS blockade.
Epstein BJ; Smith SM; Choksi R
Expert Rev Cardiovasc Ther; 2009 Nov; 7(11):1373-84. PubMed ID: 19900020
[TBL] [Abstract][Full Text] [Related]
8. Update on Hypertension Management: treatment of hypertension in patients with type 2 diabetes mellitus.
Nilsson PM; Cifkova R; Kjeldsen SE
J Hypertens; 2006 Jan; 24(1):208-10. PubMed ID: 16331123
[No Abstract] [Full Text] [Related]
9. ACE inhibitors and ARBs: are they better than other agents to slow nephropathy progression?
Bakris GL
J Clin Hypertens (Greenwich); 2007 Jun; 9(6):413-5. PubMed ID: 17541325
[No Abstract] [Full Text] [Related]
10. Renin inhibition--benefit beyond hypertension control.
Kher V
J Assoc Physicians India; 2009 Jul; 57():518-20, 525. PubMed ID: 20329413
[TBL] [Abstract][Full Text] [Related]
11. Dual renin-angiotensin system inhibition for prevention of renal and cardiovascular events: do the latest trials challenge existing evidence?
Mallat SG
Cardiovasc Diabetol; 2013 Jul; 12():108. PubMed ID: 23866091
[TBL] [Abstract][Full Text] [Related]
12. Direct renin inhibitors: ONTARGET for success?
Pasha Y; Gusbeth-Tatomir P; Covic A; Goldsmith D
Int Urol Nephrol; 2009; 41(2):341-55. PubMed ID: 19296235
[TBL] [Abstract][Full Text] [Related]
13. [The future of renin inhibition].
Uresin AY; Baran E
Turk Kardiyol Dern Ars; 2009 Oct; 37 Suppl 7():32-8. PubMed ID: 20019475
[TBL] [Abstract][Full Text] [Related]
14. Predominance of AT(1) blockade over mas-mediated angiotensin-(1-7) mechanisms in the regulation of blood pressure and renin-angiotensin system in mRen2.Lewis rats.
Varagic J; Ahmad S; VonCannon JL; Moniwa N; Brosnihan KB; Wysocki J; Batlle D; Ferrario CM
Am J Hypertens; 2013 May; 26(5):583-90. PubMed ID: 23459599
[TBL] [Abstract][Full Text] [Related]
15. [Efficacy of calcium channel blocker in hypertensive patients with chronic kidney disease].
Morihira M; Kikuchi K; Nakagawa N; Fujino T; Hasebe N
Nihon Jinzo Gakkai Shi; 2009; 51(4):451-5. PubMed ID: 19601552
[No Abstract] [Full Text] [Related]
16. Comparative role of angiotensin receptor blockers versus other agents in the management of hypertension, cardiovascular disease and nephropathy.
Tempelhof MW
South Med J; 2009 Dec; 102(12):1201-2. PubMed ID: 20016423
[No Abstract] [Full Text] [Related]
17. [Dual blockade of the renin-angiotensin system in hypertensive treatment: yes].
Middeke M
Dtsch Med Wochenschr; 2012 Nov; 137(48):2498. PubMed ID: 23168983
[No Abstract] [Full Text] [Related]
18. Renal and cardio-protective effects of direct renin inhibition: a systematic literature review.
Lambers Heerspink HJ; Perkovic V; de Zeeuw D
J Hypertens; 2009 Dec; 27(12):2321-31. PubMed ID: 19727007
[TBL] [Abstract][Full Text] [Related]
19. Rational of the use of aliskiren in hypertension and beyond.
Westermann D; Savvatis K; Schultheiss HP; Tschöpe C
Minerva Cardioangiol; 2009 Dec; 57(6):761-72. PubMed ID: 20019651
[TBL] [Abstract][Full Text] [Related]
20. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR
Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
